Viral infections have a major impact in human health. Ongoing viral transmission and
escalating selective pressure have the potential to favor the emergence of vaccine-and …

Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …

Prolonged infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in
immunocompromised patients provides an opportunity for viral evolution, potentially leading …

Lassa virus is estimated to cause thousands of human deaths per year, primarily due to
spillovers from its natural host, Mastomys rodents. Efforts to create vaccines and antibody …

Background and Objectives COVID‐19 convalescent plasma (CCP) has retained potency
and clinical efficacy against SARS‐CoV‐2 and is currently of utmost value for seronegative …

Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was
the most successful in having the longest temporal window of clinical use, showing a high …

Abstract Background Immunocompromised patients (ICPs) have an increased risk for a
severe and prolonged COVID-19. SARS-CoV-2 monoclonal antibodies (mAbs) were …

Abstract Introduction AZD7442 (tixagevimab/cilgavimab) comprises neutralising monoclonal
antibodies (mAbs) that bind to distinct non-overlapping epitopes on the severe acute …

Monoclonal antibody (mAb) therapeutics hold promise for both preventing and treating
infectious diseases, especially among vulnerable populations. However, the emergence of …

Abstract Background Immunocompromised patients (ICPs) have an increased risk for a
severe and prolonged COVID-19. SARS-CoV-2 monoclonal antibodies (mAbs) were …